NewAmsterdam Pharma (NASDAQ:NAMS) CAO Louise Frederika Kooij Sells 150,000 Shares

NewAmsterdam Pharma (NASDAQ:NAMS) CAO Louise Frederika Kooij sold 150,000 shares of NewAmsterdam Pharma stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $20.37, for a total transaction of $3,055,500.00. Following the transaction, the chief accounting officer now directly owns 15,000 shares in the company, valued at $305,550. This represents a 90.91 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

NewAmsterdam Pharma Stock Performance

Shares of NASDAQ:NAMS opened at $23.02 on Thursday. The company’s 50-day moving average is $22.30 and its 200 day moving average is $20.41. The company has a market capitalization of $2.13 billion, a P/E ratio of -8.85 and a beta of -0.06. NewAmsterdam Pharma has a fifty-two week low of $15.19 and a fifty-two week high of $27.29.

NewAmsterdam Pharma (NASDAQ:NAMS) last released its quarterly earnings data on Wednesday, February 26th. The company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.47). The business had revenue of $12.77 million for the quarter, compared to analyst estimates of $3.30 million. As a group, research analysts predict that NewAmsterdam Pharma will post -1.75 earnings per share for the current year.

Analysts Set New Price Targets

NAMS has been the topic of a number of analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $48.00 price objective on shares of NewAmsterdam Pharma in a report on Tuesday, January 14th. Royal Bank of Canada reissued an “outperform” rating and issued a $40.00 price target on shares of NewAmsterdam Pharma in a report on Friday, January 24th. Scotiabank boosted their price target on shares of NewAmsterdam Pharma from $47.00 to $52.00 and gave the stock a “sector outperform” rating in a report on Thursday, February 27th. Finally, Needham & Company LLC cut their price target on shares of NewAmsterdam Pharma from $46.00 to $42.00 and set a “buy” rating on the stock in a report on Thursday, February 27th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, NewAmsterdam Pharma presently has an average rating of “Buy” and a consensus target price of $43.80.

Institutional Investors Weigh In On NewAmsterdam Pharma

Several institutional investors have recently added to or reduced their stakes in the business. GF Fund Management CO. LTD. purchased a new stake in NewAmsterdam Pharma during the fourth quarter valued at about $50,000. Frazier Life Sciences Management L.P. lifted its holdings in NewAmsterdam Pharma by 23.8% during the fourth quarter. Frazier Life Sciences Management L.P. now owns 15,916,418 shares of the company’s stock valued at $409,052,000 after purchasing an additional 3,061,224 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in NewAmsterdam Pharma by 6.0% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 253,571 shares of the company’s stock valued at $6,517,000 after purchasing an additional 14,288 shares during the last quarter. Voloridge Investment Management LLC purchased a new stake in NewAmsterdam Pharma during the fourth quarter valued at about $721,000. Finally, Woodline Partners LP lifted its holdings in NewAmsterdam Pharma by 108.7% during the fourth quarter. Woodline Partners LP now owns 2,430,782 shares of the company’s stock valued at $62,471,000 after purchasing an additional 1,266,105 shares during the last quarter. 89.89% of the stock is owned by hedge funds and other institutional investors.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.